Thousand Oaks Biopharmaceuticals has raised $109M in total funding. Latest round: Series B. Backed by CICC Jiatai, Goldstone Investment, CCB International.
Thousand Oaks Biopharmaceuticals funding overview
Thousand Oaks Biopharmaceuticals has raised $109M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in July 2026. The round record for Thousand Oaks Biopharmaceuticals runs through 2026; nothing later has been disclosed. Investors on record include CICC Jiatai, Goldstone Investment, CCB International, Wens Investment, Shanghai Huaxu Investment. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Thousand Oaks Biopharmaceuticals funding
How much has Thousand Oaks Biopharmaceuticals raised?
Thousand Oaks Biopharmaceuticals has raised $109M in total disclosed funding across the rounds on record.
Who has invested in Thousand Oaks Biopharmaceuticals?
CICC Jiatai, Goldstone Investment, CCB International, Wens Investment, Shanghai Huaxu Investment are named among the investors backing Thousand Oaks Biopharmaceuticals.
What was the latest Thousand Oaks Biopharmaceuticals funding round?
The most recent disclosed round is a Series B, announced in July 2026.
Where is Thousand Oaks Biopharmaceuticals based?
No headquarters location is disclosed for Thousand Oaks Biopharmaceuticals.
When did Thousand Oaks Biopharmaceuticals last raise?
The last disclosed Thousand Oaks Biopharmaceuticals round closed in July 2026 at Series B.
Round data for Thousand Oaks Biopharmaceuticals is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies and backer lists below.
Companies related to Thousand Oaks Biopharmaceuticals (30)
